Terms: = Prostate cancer AND TAF15, hTAFII68, 8148, ENSG00000172660, TAF2N, RBP56, Npl3, Q92804
3 results:
1. Variation in the methodological approach to productivity cost valuation: the case of prostate cancer.
Hanly P; Maguire R; Drummond F; Sharp L
Eur J Health Econ; 2019 Dec; 20(9):1399-1408. PubMed ID: 31444674
[TBL] [Abstract] [Full Text] [Related]
2. [A new WHO classification of prostate tumors].
Frank GA; Andreeva YY; Moskvina LV; Efremov GD; Samoilova SI
Arkh Patol; 2016; 78(4):32-42. PubMed ID: 27600780
[TBL] [Abstract] [Full Text] [Related]
3. [Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].
Kesch C; Radtke JP; Distler F; Boxler S; Klein T; Hüttenbrink C; Hees K; Roth W; Roethke M; Schlemmer HP; Hohenfellner M; Hadaschik BA
Urologe A; 2016 Aug; 55(8):1071-7. PubMed ID: 27168038
[TBL] [Abstract] [Full Text] [Related]
